Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Anja Heinemann"'
Autor:
Annette Paschen, Dirk Schadendorf, Sven Diederichs, Alexander Steinle, Jürgen Eberle, Sonali Pechlivanis, Fang Zhao, Anja Heinemann
PDF file - 277K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::124f703af275d91fc7d255045676cd61
https://doi.org/10.1158/0008-5472.22392750
https://doi.org/10.1158/0008-5472.22392750
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Table legend. Supplementary Table legends S1, S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4036de5a9bb9f47536dd1723903dfb56
https://doi.org/10.1158/0008-5472.22408008.v1
https://doi.org/10.1158/0008-5472.22408008.v1
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Information. Detailed material information, methods and supplemental figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055ccd7abc1949964a65e517f06e2484
https://doi.org/10.1158/0008-5472.22408020
https://doi.org/10.1158/0008-5472.22408020
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Figure 1. CEACAM1-3S modulates melanoma cell sensitivity against NK cell-mediated cytolysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab470f87e7a59596654072cd7322b98
https://doi.org/10.1158/0008-5472.22408026
https://doi.org/10.1158/0008-5472.22408026
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Table 2. Quantitative expression analyses of CEACAM1 splice variants in melanoma biopsies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4580648e2808f2df71b89f218cba2ae7
https://doi.org/10.1158/0008-5472.22408011.v1
https://doi.org/10.1158/0008-5472.22408011.v1
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Table 1. Quantitative expression of CEACAM1 splice variants in melanoma cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55adf27e280da85ee001e9f164e1d8a9
https://doi.org/10.1158/0008-5472.22408014
https://doi.org/10.1158/0008-5472.22408014
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
CEACAM1 is a widely expressed multifunctional cell–cell adhesion protein reported to serve as a poor prognosis marker in melanoma patients. In this study, we examine the functional and clinical contributions of the four splice isoforms of CEACAM1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d35d6fdd253c482af326a86cf5e2c6f
https://doi.org/10.1158/0008-5472.c.6507441.v1
https://doi.org/10.1158/0008-5472.c.6507441.v1
Autor:
Iris Helfrich, Bernhard B. Singer, Dirk Schadendorf, André Scherag, Joachim Klode, Inka Scheffrahn, Elena Nilewski, Anja Heinemann, Nico Ullrich
Supplementary Figure 2. CEACAM1 isoforms also modulate surface expression of DNMA-1 ligands in an isoform specific mode of action.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f829747bdc84e03ba4e4a266c2b1b5
https://doi.org/10.1158/0008-5472.22408023
https://doi.org/10.1158/0008-5472.22408023
Autor:
Peter M. Ferguson, Stuart J. Gallagher, Dilini Gunatilake, Jason Madore, Kimberley A. Beaumont, James S. Wilmott, Wolfgang Weninger, Anja Heinemann, Peter Hersey, Danae M. Sharp, Jessamy Tiffen, Helen Rizos, Nikolas K. Haass
Publikováno v:
International Journal of Cancer. 142:1926-1937
Mutations in BRAF activate oncogenic MAPK signalling in almost half of cutaneous melanomas. Inhibitors of BRAF (BRAFi) and its target MEK are widely used to treat melanoma patients with BRAF mutations but unfortunately acquired resistance occurs in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b232ea533606543d20604da26280eb76
https://doi.org/10.1002/ijc.31199
https://doi.org/10.1002/ijc.31199
Autor:
Stuart J, Gallagher, Dilini, Gunatilake, Kimberley A, Beaumont, Danae M, Sharp, Jessamy C, Tiffen, Anja, Heinemann, Wolfgang, Weninger, Nikolas K, Haass, James S, Wilmott, Jason, Madore, Peter M, Ferguson, Helen, Rizos, Peter, Hersey
Publikováno v:
International journal of cancer. 142(9)
Mutations in BRAF activate oncogenic MAPK signalling in almost half of cutaneous melanomas. Inhibitors of BRAF (BRAFi) and its target MEK are widely used to treat melanoma patients with BRAF mutations but unfortunately acquired resistance occurs in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2aad0d927dd4d24474ecc28709fa0d29
https://pubmed.ncbi.nlm.nih.gov/29210065
https://pubmed.ncbi.nlm.nih.gov/29210065